Using Existing Drugs in New Ways to Treat & Cure Diseases of Brain & Body | Dr. David Fajgenbaum

概览

This episode centers on a blunt question: how many treatments for serious diseases may already exist inside the catalog of approved medicines, but remain unused because the medical and commercial systems are not designed to discover every possible use.

Dr. David Fagenbaum describes his own near-death experience with Castleman disease, the death of his mother from glioblastoma, and how those experiences pushed him toward drug repurposing. The discussion repeatedly returns to patient agency: finding disease organizations, consulting leading experts, asking better questions, and recognizing that even excellent doctors may not know every relevant treatment pathway.

The conversation also explores Every Cure, a nonprofit that uses biomedical knowledge, AI, laboratory work, clinical trials, and expert review to match existing drugs to diseases. Examples include aspirin, Viagra, lidocaine, thalidomide, pembrolizumab, DFMO, colchicine, sirolimus, TNF inhibitors, and GLP-1 drugs.

分段落总结

[00:00] The Core Premise: Existing Drugs May Still Hold Untapped Cures

[事实] David recalls being told by his doctor that all known options had been exhausted after multiple chemotherapies and an experimental drug. [事实] He questioned whether another approved drug, originally made for another disease, might still help him or other patients. [事实] Huberman introduces the episode as a discussion about repurposing approved drugs for rare and common diseases.

[05:00] Patient Agency and the Blind Spot in Medicine

[事实] David says there are about 4,000 FDA-approved drugs approved for about 4,000 diseases, while many drugs may work in additional conditions. [事实] He recommends that seriously ill patients connect with disease advocacy organizations, seek leading experts, and keep asking whether other options exist. [推测] The episode frames patient self-advocacy as a necessary supplement to clinical care, not a replacement for physicians.

[07:20] Familiar Drugs with Less Familiar Uses

[事实] Aspirin is discussed as a pain reliever, a heart attack risk reducer, and a drug shown to reduce colon cancer recurrence risk in some patients. [事实] Viagra is described as having been repurposed from heart disease research to erectile dysfunction and also to a rare pediatric lung disease. [事实] David says the average small-molecule drug can bind 20 to 30 proteins, meaning a drug may affect more systems than its main approved use suggests.

[08:58] Lidocaine and Breast Cancer Surgery

[事实] David describes a trial in India involving 1,600 patients with localized breast cancer where lidocaine injected around the tumor before surgery was associated with a 29% reduction in five-year mortality. [事实] He says lidocaine is inexpensive, widely available, and already used around surgery, yet uptake for this use has been limited. [事实] Every Cure is reviewing the evidence and studying possible mechanisms before broadly encouraging use.

[14:22] Patents, Generics, and Incentives

[事实] Huberman and David discuss how companies may change dose or formulation near a patent cliff to preserve intellectual property around an existing disease market. [事实] David says 80% of the 4,000 approved drugs are already generic, leaving little commercial incentive to study new uses. [事实] He also says there are still about 14,000 diseases without a single treatment.

[18:48] How Patients Can Look for Better Information

[事实] David recommends starting with disease-specific organizations, such as the Castleman Disease Collaborative Network, ALS Association, or Michael J. Fox Foundation. [事实] He also recommends identifying the world’s expert for a disease and asking whether treatments are being used elsewhere. [推测] The practical message is that medical knowledge is unevenly distributed, so access to the right network can affect outcomes.

[20:03] DATA2 and TNF Inhibitors

[事实] David describes DATA2 as a rare condition where children can have repeated strokes from birth and often die young. [事实] A doctor tried a TNF inhibitor in a child with DATA2, after using it for vasculitis, and the child stopped having strokes. [事实] David says years passed before the knowledge spread widely, even though TNF inhibitors could change lives for affected children.

[24:45] Thalidomide as a Repurposing Example

[事实] Thalidomide is described as a drug associated with severe birth defects after use for nausea in pregnancy. [事实] David says it was later approved for leprosy and then for multiple myeloma. [事实] He links these effects to thalidomide’s anti-angiogenic action, which can harm limb development but also affect diseases involving blood vessel growth.

[26:50] Pembrolizumab and Angiosarcoma

[事实] David’s lab helped a patient with metastatic angiosarcoma by finding a 2013 paper showing increased PD-L1 expression in four of five tumors studied. [事实] They treated the patient with a PD-1 inhibitor, and David says the patient entered a nine-year remission. [事实] He says this changed clinical practice for angiosarcoma, with responses in about 18% of patients.

[30:17] The Need for Better Databases and AI Translation

[事实] Huberman argues that patients should be able to enter family history, symptoms, and disease information into a database that connects them to evidence and experts. [事实] David says Every Cure maps biomedical knowledge and uses AI and machine learning to estimate how likely every drug is to treat every disease. [事实] He emphasizes proving promising connections through lab work and clinical trials, not just listing speculative links.

[34:27] From Common Diseases to Ultra-Rare Syndromes

[事实] Every Cure has active programs ranging from lidocaine for breast cancer to DFMO for Bachman-Bupp syndrome. [事实] David says children with Bachman-Bupp syndrome have elevated OCE 1 enzyme activity and severe developmental problems, and DFMO can help if started early enough. [事实] Colchicine is discussed as an old gout drug that later received FDA approval for reducing heart disease risk in a specific prior-heart-attack population.

[41:28] David’s Path Into Medicine

[事实] David says his mother’s glioblastoma diagnosis during his freshman year at Georgetown changed his life. [事实] Before she died, he told her he would dedicate his life to finding treatments for patients like her, and she responded with the words “unconditional love.” [事实] He describes her humor after brain surgery as a model of taking agency back from illness.

[46:46] Castleman Disease and Near-Death Illness

[事实] As a medical student, David developed enlarged lymph nodes, extreme fatigue, abdominal pain, ankle fluid, and multi-organ failure. [事实] He gained about 100 pounds of fluid, required transfusions and dialysis, temporarily lost vision in one eye, and received last rites at age 25. [事实] A lymph node biopsy led to a Castleman disease diagnosis after doctors initially considered lymphoma and autoimmune disease.

[49:10] Stress, Sleep, Cytokines, and Early Treatments

[事实] Huberman asks whether long medical-school hours and intense athletic drive may have contributed to immune dysfunction. [事实] David mentions a mouse study where severe sleep deprivation killed mice through cytokine storm involving immune activation. [事实] David says tocilizumab was approved for Castleman disease in Japan but was not initially tried by his U.S. doctors; chemotherapy ultimately saved his life temporarily.

[63:36] Relapse, “Out of Options,” and Self-Experiment-Informed Research

[事实] After remission, David relapsed again while on an experimental drug and was told no options remained. [事实] He began storing his own blood samples, running flow cytometry, measuring serum proteins, and studying drugs used in related conditions. [事实] After another near-fatal relapse, he used new samples and lymph node analysis to identify mTOR activation.

[70:17] Sirolimus, mTOR, and Long Remission

[事实] David asked his doctor to prescribe sirolimus, also known as rapamycin, an mTOR inhibitor approved for organ transplant rejection. [事实] He says sirolimus had never been used for Castleman disease before. [事实] He reports being in remission for 11 and three-quarter years on sirolimus after nearly dying five times in the prior three and a half years.

[73:50] Football, Pain, and Resilience

[事实] David credits football with teaching him long-term goal pursuit, repeated recovery after losses, and tolerance for physical pain. [事实] He says he had poster boards tracking athletic goals from childhood and worked for 10 years toward becoming a Division I quarterback. [事实] In the ICU, he relied on a future vision, family support, and the ability to endure one breath, minute, hour, or day at a time.

[83:39] Scaling Lessons Beyond Castleman Disease

[事实] David attended business school because he saw collaboration, resource use, and strategy as major barriers to medical progress. [事实] His lab first focused on Castleman disease, then found that sirolimus helped other patients, including a child named Joey. [事实] The lab also recommended ruxolitinib for a patient named Kyla and later worked on angiosarcoma, contributing to a total of 14 repurposed drug uses.

[87:52] Every Cure’s AI-Driven Model and Hail Mary Cases

[事实] Every Cure was founded to use AI across all drugs and diseases rather than one company or one drug at a time. [事实] David describes a Castleman patient named Al who responded to adalimumab, a TNF inhibitor ranked highly by their machine-learning model. [事实] He also describes a POEMS syndrome patient named Joseph who improved after doctors tried three drugs typically used for multiple myeloma.

[92:54] Safety, Risk, and Responsible Repurposing

[事实] Huberman raises concern that a harmful outcome from a novel use of an existing drug could set back an entire field. [事实] David says Every Cure tries to avoid speculative “Hail Mary” recommendations unless evidence is solid. [事实] He says their approach includes laboratory studies, clinical trials, observational data, expert review, and final prescribing decisions between physician and patient.

[96:00] Prevention, Supplements, Natural Products, and Drug Boundaries

[事实] Huberman discusses nicotine, lithium, and other compounds some physicians use or consider for prevention, while warning about risks and addictive potential. [事实] David discusses GLP-1 drugs as an area where evidence is emerging around Parkinson’s symptoms, Alzheimer’s risk, and breast cancer risk. [事实] Rapamycin is described as a compound found in soil from Rapa Nui, later developed as an immunosuppressant and approved for transplant rejection.

[104:12] AI as a Tool for Connecting Existing Evidence

[事实] David says AI is useful not only for simulating new experiments but for connecting research findings that already exist across labs, cell studies, animal models, and human data. [事实] He uses the PD-L1 and PD-1 example to explain how separate facts can be linked into a treatment hypothesis. [推测] The proposed role of AI is prioritization: helping humans decide where to focus limited experimental and clinical resources.

[147:09] Hope, Action, Impact, and the Will to Live

[事实] David describes a “hope, action, impact” circuit where hope drives action, action produces impact, and impact creates more hope. [事实] Huberman connects this to the anterior mid-cingulate cortex, tenacity, challenge-seeking, dopamine-related networks, and findings from superagers. [事实] Huberman describes a practical strategy of shortening the horizon during hard challenges and iterating around path, duration, and outcome.

[152:50] How People Can Contribute to Every Cure

[事实] David says people can submit off-label drug ideas, expert input, awareness support, or donations through Every Cure. [事实] He says Every Cure is funded about half by ARPA-H and about half by individuals. [事实] He says the organization is nonprofit, though rare cases may require a new formulation or company if a drug must be modified to reach the brain.

播客点评/总结

[推测] The strongest value of this episode is its combination of personal narrative and systems critique. David’s story makes the abstract problem of drug repurposing concrete, while the examples show how missed connections can have life-or-death consequences.

[推测] The episode is especially useful for patients, caregivers, physicians, researchers, and health advocates who want a framework for asking better questions without treating internet searches as medical authority.

[推测] Its main limitation is that many examples are promising or case-based, and the discussion itself repeatedly notes the need for mechanisms, clinical trials, observational data, and physician oversight before broad adoption.

[推测] As a publishable summary, the practical takeaway is clear: approved drugs may have underused potential, but the responsible path is organized evidence discovery, careful validation, and collaborative decision-making between patients, experts, and clinicians.